Tonix Reports Commitment To Supply Tosymra For Treatment Of Acute Migraine To Meet Potential Increased Demand Following GSK's Planned Discontinuation Of Imitrex Nasal Spray After January 2024
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals (TNXP) has committed to supplying Tosymra, a treatment for acute migraine, to meet potential increased demand following GlaxoSmithKline's (GSK) planned discontinuation of Imitrex nasal spray after January 2024.
September 06, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GlaxoSmithKline's planned discontinuation of Imitrex nasal spray may lead to a decrease in revenues from this product line.
GSK's decision to discontinue Imitrex nasal spray could lead to a decrease in revenues from this product line. This could negatively impact its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Tonix Pharmaceuticals may see increased demand for its product Tosymra following GSK's discontinuation of a similar product.
Tonix's commitment to supply Tosymra in anticipation of increased demand following the discontinuation of a similar product by GSK indicates a potential market opportunity for Tonix. This could positively impact its revenues and stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100